National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved August 1997

Specific Treatments:

Kaposi's Sarcoma

General Information

The U.S. Food and Drug Administration approved Bristol-Myers Squibb's cancer drug Taxol for the treatment of AIDS-related Kaposi's Sarcoma. Taxol therapy reduces the size of patients' tumors and diminishes their symptoms and pain. Taxol helped a majority of patients who had failed other therapies.